Tllsh2910

Phase 3Small molecule

NNational Taiwan University Hospital

Tllsh2910 is one of 29 small molecule programs targeting Multiple System Atrophy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple System AtrophyActive, not recruiting

Multiple System AtrophyPhase 3

Active, not recruiting

Competition

Competitive Landscape

48 competitors in Multiple System Atrophy

#DrugCompanyPhaseTrials

Northera

Rifadin

Rilutek

AAzurity Pharmaceuticals

Sudafed

Rifampicin

1 6

Byetta

AstraZeneca

Phase 2

—7

Lithobid

SSolvay Pharmaceuticals

Phase 2

1 8

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 2

1 9

Rapamune

PPrism Pharmaceuticals

Phase 2

1 10

Immunoglobulin

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Multiple System Atrophy1 trial

Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System Atrophy

Terminated·NNational Taiwan University Hospital·Phase 3·NCT03901638·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tllsh2910. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tllsh2910 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tllsh2910. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Taiwan University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNational Taiwan University Hospital

Tllsh2910

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Multiple System Atrophy1 trial

References

Drug Info

Quick Facts

Related News